通常来说，在国内创新药领域，一家公司季度营收的持续增长和盈利拐点的到来，意味着公司发展向好并进入商业化新周期。然而，近期再鼎医药交出一份数据增长稳健的中报后，港股和美股的股价却双双大跌，这是为何？再鼎医药作为中国License-in模式（指获取授权将产品引入境内）的开创者和标杆企业，2025年上半年实现总收入2.16亿美元，同比增长15.35%，净亏损同比收窄33.33%，各项财务指标均显示出积极...
Source Link通常来说，在国内创新药领域，一家公司季度营收的持续增长和盈利拐点的到来，意味着公司发展向好并进入商业化新周期。然而，近期再鼎医药交出一份数据增长稳健的中报后，港股和美股的股价却双双大跌，这是为何？再鼎医药作为中国License-in模式（指获取授权将产品引入境内）的开创者和标杆企业，2025年上半年实现总收入2.16亿美元，同比增长15.35%，净亏损同比收窄33.33%，各项财务指标均显示出积极...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.